secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENXBIO Inc. (RGNX)
CIK:        0001590877
Form:       8-K
Filed at:   2024-02-27T23:59:59+00:00
Accession:  0000950170-24-021130
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

REGENXBIO reports Q4 net loss $62.9M, cash $314M; pipeline milestones for 2024
------------------------------------------------------------------------------

- Q4 net loss $62.9M ($1.43/sh); full year net loss $263.5M ($6.02/sh); 2023 revenue $90.2M vs $112.7M in 2022.
- Cash, cash equivalents and marketable securities $314.1M as of Dec 31, 2023; expected to fund operations into H2 2025.
- ABBV-RGX-314 wet AMD subretinal pivotal trials on track for global submissions late 2025-early 2026; suprachoroidal data mid-2024.
- RGX-202 Duchenne pivotal dose determination mid-2024; RGX-121 MPS II BLA filing planned for 2024 via accelerated approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590877/000095017024021130/0000950170-24-021130-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590877/000095017024021130/rgnx-20240227.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-021130

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer